Multi-level omics analysis in a murine model of dystrophin loss and therapeutic restoration

Human Molecular Genetics

Volumn 24, Issue 23, 2015, Pages 6756-6768

  Roberts, Thomas C ^a,b   Johansson, Henrik J ^c   McClorey, Graham ^a   Godfrey, Caroline ^c   Blomberg, Emelie K M ^c   Coursindel, Thibault ^d   Gait, Michael J ^d   Edvard Smith, C I ^c   Lehtiö, Janne ^c   Andaloussi, Samir E L ^a,c   Wood, Matthew J A ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b BURNHAM INSTITUTE   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

^d MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DYSTROPHIN; IODOACETAMIDE; MICRORNA; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOINFORMATICS; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; EXON SKIPPING; GENE EXPRESSION; ISOELECTRIC FOCUSING; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MICROARRAY ANALYSIS; MOUSE; MULTIOMICS; MURINE MODEL; NONHUMAN; PRINCIPAL COMPONENT ANALYSIS; PROTEIN EXPRESSION; TIBIALIS ANTERIOR MUSCLE; TRANSCRIPTOMICS; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE; ANIMAL; DISEASE MODEL; GENE EXPRESSION PROFILING; GENE THERAPY; GENETICS; MALE; METABOLISM; MUSCULAR DYSTROPHY, ANIMAL; MUSCULAR DYSTROPHY, DUCHENNE; MUTATION; PATHOPHYSIOLOGY; PROTEOMICS; SKELETAL MUSCLE;

ANIMALS; DISEASE MODELS, ANIMAL; DYSTROPHIN; GENE EXPRESSION PROFILING; GENETIC THERAPY; MALE; MICE; MICE, INBRED MDX; MICRORNAS; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, ANIMAL; MUSCULAR DYSTROPHY, DUCHENNE; MUTATION; PROTEOMICS; RNA, MESSENGER;

EID: 84949449468     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddv381     Document Type: Article

References (83)

1. Hoffman, E.P., Brown, R.H. Jr and Kunkel, L.M. (1987) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell, 51, 919–928.
2. Monaco, A.P., Bertelson, C.J., Liechti-Gallati, S., Moser, H. and Kunkel, L.M. (1988) An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics, 2, 90–95.
3. Ervasti, J.M. and Campbell, K.P. (1991) Membrane organization of the dystrophin-glycoprotein complex. Cell, 66, 1121–1131.
4. Campbell, K.P. (1995) Three muscular dystrophies: loss of cytoskeleton-extracellular matrix linkage. Cell, 80, 675–679.
5. Petrof, B.J., Shrager, J.B., Stedman, H.H., Kelly, A.M. and Sweeney, H.L. (1993) Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc. Natl Acad. Sci. U.S.A., 90, 3710–3714.
6. Koenig, M., Hoffman, E.P., Bertelson, C.J., Monaco, A.P., Feener, C. and Kunkel, L.M. (1987) Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell, 50, 509–517.
7. Cirak, S., Arechavala-Gomeza, V., Guglieri, M., Feng, L., Torelli, S., Anthony, K., Abbs, S., Garralda, M.E., Bourke, J., Wells, D.J. et al. (2011) Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet, 378, 595–605.
8. Van Deutekom, J.C., Janson, A.A., Ginjaar, I.B., Frankhuizen, W.S., Aartsma-Rus, A., Bremmer-Bout, M., den Dunnen, J.T., Koop, K., van der Kooi, A.J., Goemans, N.M. et al. (2007) Local dystrophin restoration with antisense oligonucleotide PRO051. N. Engl. J. Med., 357, 2677–2686.
9. Goemans, N.M., Tulinius, M., van den Akker, J.T., Burm, B.E., Ekhart, P.F., Heuvelmans, N., Holling, T., Janson, A.A., Platen-burg, G.J., Sipkens, J.A. et al. (2011) Systemic administration of PRO051 in Duchenne’s muscular dystrophy. N. Engl. J. Med., 364, 1513–1522.
10. Kinali, M., Arechavala-Gomeza, V., Feng, L., Cirak, S., Hunt, D., Adkin, C., Guglieri, M., Ashton, E., Abbs, S., Nihoyannopoulos, P. et al. (2009) Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol., 8, 918–928.
11. Mendell, J.R., Rodino-Klapac, L.R., Sahenk, Z., Roush, K., Bird, L., Lowes, L.P., Alfano, L., Gomez, A.M., Lewis, S., Kota, J. et al. (2013) Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann. Neurol., 74, 637–647.
12. Betts, C., Saleh, A.F., Arzumanov, A.A., Hammond, S.M., Godfrey, C., Coursindel, T., Gait, M.J. and Wood, M.J. (2012) Pip6-PMO, a new generation of peptide-oligonucleotide conjugates with improved cardiac exon skipping activity for DMD treatment. Mol. Ther. Nucleic Acids, 1, e38.
13. Roberts, T.C., Godfrey, C., McClorey, G., Vader, P., Briggs, D., Gardiner, C., Aoki, Y., Sargent, I., Morgan, J.E. and Wood, M.J.A. (2013) Extracellular microRNAs are dynamic non-vesicular biomarkers of muscle turnover. Nucl. Acids Res., 41, 9500–9513.
14. Yin, H., Moulton, H.M., Betts, C., Seow, Y., Boutilier, J., Iverson, P.L. and Wood, M.J.A. (2009) A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice. Hum. Mol. Genet, 18, 4405–4414.
15. Yin, H., Saleh, A.F., Betts, C., Camelliti, P., Seow, Y., Ashraf, S., Arzumanov, A., Hammond, S., Merritt, T., Gait, M.J. et al. (2011) Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. Mol. Ther., 19, 1295–1303.
16. Bulfield, G., Siller, W.G., Wight, P.A. and Moore, K.J. (1984) X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc. Natl Acad. Sci. U.S.A., 81, 1189–1192.
17. Sicinski, P., Geng, Y., Ryder-Cook, A.S., Barnard, E.A., Darlison, M.G. and Barnard, P.J. (1989) The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science, 244, 1578–1580.
18. Ohlendieck, K. (2011) Skeletal muscle proteomics: current approaches, technical challenges and emerging techniques. Skelet Muscle, 1, 6.
19. Aebersold, R. and Mann, M. (2003) Mass spectrometry-based proteomics. Nature, 422, 198–207.
20. Gygi, S.P., Corthals, G.L., Zhang, Y., Rochon, Y. and Aebersold, R. (2000) Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology. Proc. Natl Acad. Sci. U.S.A., 97, 9390–9395.
21. Branca, R.M.M., Orre, L.M., Johansson, H.J., Granholm, V., Huss, M., Pérez-Bercoff, Å., Forshed, J., Käll, L. and Lehtiö, J. (2014) HiRIEF LC-MS enables deep proteome coverage and unbiased proteogenomics. Nat. Methods, 11, 59–62.
22. Johansson, H.J., Sanchez, B.C., Mundt, F., Forshed, J., Kovacs, A., Panizza, E., Hultin-Rosenberg, L., Lundgren, B., Martens, U., Máthé, G. et al. (2013) Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer. Nat. Commun., 4, 2175.
23. Ideker, T., Thorsson, V., Ranish, J.A., Christmas, R., Buhler, J., Eng, J.K., Bumgarner, R., Goodlett, D.R., Aebersold, R. and Hood, L. (2001) Integrated genomic and proteomic analyses of a systematically perturbed metabolic network. Science, 292, 929–934.
24. Zhang, W., Li, F. and Nie, L. (2010) Integrating multiple ‘omics’ analysis for microbial biology: application and methodologies. Microbiology, 156, 287–301.
25. De Sousa Abreu, R., Penalva, L.O., Marcotte, E.M. and Vogel, C. (2009) Global signatures of protein and mRNA expression levels. Mol. Biosyst., 5, 1512–1526.
26. Maier, T., Güell, M. and Serrano, L. (2009) Correlation of mRNA and protein in complex biological samples. FEBS Lett., 583, 3966–3973.
27. Nie, L., Wu, G. and Zhang, W. (2006) Correlation between mRNA and protein abundance in Desulfovibrio vulgaris: a multiple regression to identify sources of variations. Biochem. Biophys. Res. Commun., 339, 603–610.
28. Gygi, S.P., Rochon, Y., Franza, B.R. and Aebersold, R. (1999) Correlation between protein and mRNA abundance in yeast. Mol. Cell. Biol., 19, 1720–1730.
29. Chen, G., Gharib, T.G., Huang, C.-C., Taylor, J.M.G., Misek, D.E., Kardia, S.L.R., Giordano, T.J., Iannettoni, M.D., Orringer, M.B., Hanash, S.M. et al. (2002) Discordant protein and mRNA expression in lung adenocarcinomas. Mol. Cell Proteomics, 1, 304–313.
30. Schwanhäusser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W. and Selbach, M. (2011) Global quantification of mammalian gene expression control. Nature, 473, 337–342.
31. Roberts, T.C. and Wood, M.J. (2014) Non-canonical microRNA biogenesis and function. In Applied RNAi: From Fundamental Research to Therapeutic Applications. Caister Academic Press, pp. 19–42.
32. Lim, L.P., Lau, N.C., Garrett-Engele, P., Grimson, A., Schelter, J.M., Castle, J., Bartel, D.P., Linsley, P.S. and Johnson, J.M. (2005) Microarray analysis shows that some microRNAs down-regulate large numbers of target mRNAs. Nature, 433, 769–773.
33. Guo, H., Ingolia, N.T., Weissman, J.S. and Bartel, D.P. (2010) Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature, 466, 835–840.
34. Baek, D., Villén, J., Shin, C., Camargo, F.D., Gygi, S.P. and Bartel, D.P. (2008) The impact of microRNAs on protein output. Nature, 455, 64–71.
35. Selbach, M., Schwanhäusser, B., Thierfelder, N., Fang, Z., Khanin, R. and Rajewsky, N. (2008) Widespread changes in protein synthesis induced by microRNAs. Nature, 455, 58–63.
36. Roberts, T.C., Blomberg, K.E.M., McClorey, G., Andaloussi, S.E., Godfrey, C., Betts, C., Coursindel, T., Gait, M.J., Smith, C.E. and Wood, M.J. (2012) Expression analysis in multiple muscle groups and serum reveals complexity in the MicroRNA transcriptome of the mdx mouse with implications for therapy. Mol. Ther. Nucleic Acids, 1, e39.
37. Betel, D., Wilson, M., Gabow, A., Marks, D.S. and Sander, C. (2008) The microRNA.org resource: targets and expression. Nucleic Acids Res., 36, D149–D153.
38. Lewis, B.P., Shih, I., Jones-Rhoades, M.W., Bartel, D.P. and Burge, C.B. (2003) Prediction of mammalian microRNA targets. Cell, 115, 787–798.
39. Bartel, D.P. (2009) MicroRNA target recognition and regulatory functions. Cell, 136, 215–233.
40. Lewis, B.P., Burge, C.B. and Bartel, D.P. (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell, 120, 15–20.
41. Huang, J.C., Babak, T., Corson, T.W., Chua, G., Khan, S., Gallie, B.L., Hughes, T.R., Blencowe, B.J., Frey, B.J. and Morris, Q.D. (2007) Using expression profiling data to identify human microRNA targets. Nat. Meth., 4, 1045–1049.
42. Arechavala-Gomeza, V., Kinali, M., Feng, L., Guglieri, M., Edge, G., Main, M., Hunt, D., Lehovsky, J., Straub, V., Bushby, K. et al. (2010) Revertant fibres and dystrophin traces in Duchenne muscular dystrophy: implication for clinical trials. Neuromuscul. Disord., 20, 295–301.
43. Pigozzo, S.R., Da Re, L., Romualdi, C., Mazzara, P.G., Galletta, E., Fletcher, S., Wilton, S.D. and Vitiello, L. (2013) Revertant fibers in the mdx murine model of duchenne muscular dystrophy: an age- and muscle-related reappraisal. PLoS ONE, 8, e72147.
44. Ting, L., Rad, R., Gygi, S.P. and Haas, W. (2011) MS3 eliminates ratio distortion in isobaric multiplexed quantitative proteomics. Nat. Methods, 8, 937–940.
45. Even, P.C., Decrouy, A. and Chinet, A. (1994) Defective regulation of energy metabolism in mdx-mouse skeletal muscles. Biochem. J., 304 (Pt 2), 649–654.
46. Andreetta, F., Bernasconi, P., Baggi, F., Ferro, P., Oliva, L., Arnoldi, E., Cornelio, F., Mantegazza, R. and Confalonieri, P. (2006) Immunomodulation of TGF-beta 1 in mdx mouse inhibits connective tissue proliferation in diaphragm but increases inflammatory response: implications for antifibrotic therapy. J. Neuroimmunol., 175, 77–86.
47. Sun, G., Haginoya, K., Wu, Y., Chiba, Y., Nakanishi, T., Onuma, A., Sato, Y., Takigawa, M., Iinuma, K. and Tsuchiya, S. (2008) Connective tissue growth factor is overexpressed in muscles of human muscular dystrophy. J. Neurol. Sci., 267, 48–56.
48. Wang, L., Zhou, L., Jiang, P., Lu, L., Chen, X., Lan, H., Guttridge, D.C., Sun, H. and Wang, H. (2012) Loss of miR-29 in myoblasts contributes to dystrophic muscle pathogenesis. Mol. Ther., 20, 1222–1233.
49. Wang, B., Haldar, S.M., Lu, Y., Ibrahim, O.A., Fisch, S., Gray, S., Leask, A. and Jain, M.K. (2008) The Kruppel-like factor KLF15 inhibits connective tissue growth factor (CTGF) expression in cardiac fibroblasts. J. Mol. Cell. Cardiol., 45, 193–197.
50. Guevel, L., Lavoie, J.R., Perez-Iratxeta, C., Rouger, K., Dubreil, L., Feron, M., Talon, S., Brand, M. and Megeney, L.A. (2011) Quantitative proteomic analysis of dystrophic dog muscle. J. Proteome Res., 10, 2465–2478.
51. Chan, M.C. and Arany, Z. (2014) The many roles of PGC-1α in muscle–recent developments. Metab. Clin. Exp., 63, 441–451.
52. Wu, Z., Puigserver, P., Andersson, U., Zhang, C., Adelmant, G., Mootha, V., Troy, A., Cinti, S., Lowell, B., Scarpulla, R.C. et al. (1999) Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell, 98, 115–124.
53. Handschin, C., Kobayashi, Y.M., Chin, S., Seale, P., Campbell, K.P. and Spiegelman, B.M. (2007) PGC-1α regulates the neuromuscular junction program and ameliorates Duchenne muscular dystrophy. Genes Dev., 21, 770–783.
54. Kumar, A. and Boriek, A.M. (2003) Mechanical stress activates the nuclear factor-kappaB pathway in skeletal muscle fibers: a possible role in Duchenne muscular dystrophy. FASEB J., 17, 386–396.
55. Betts, C.A., Saleh, A.F., Carr, C.A., Hammond, S.M., Coenen-Stass, A.M.L., Godfrey, C., McClorey, G., Varela, M.A., Roberts, T.C., Clarke, K. et al. (2015) Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice. Sci. Rep., 5, 8986.
56. Godfrey, C., Muses, S., McClorey, G., Wells, K.E., Coursindel, T., Terry, R.L., Betts, C., Hammond, S., O’Donovan, L., Hildyard, J. et al. (2015) How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouse. Hum. Mol. Genet., 24, 4225–4237.
57. ‘t Hoen, P.A.C., van der Wees, C.G.C., Aartsma-Rus, A., Turk, R., Goyenvalle, A., Danos, O., Garcia, L., van Ommen, G.-J.B., den Dunnen, J.T. and van Deutekom, J.C.T. (2006) Gene expression profiling to monitor therapeutic and adverse effects of antisense therapies for Duchenne muscular dystrophy. Pharmacogenomics, 7, 281–297.
58. Fisher, I., Abraham, D., Bouri, K., Hoffmann, E.P., Hoffman, E.P., Muntoni, F. and Morgan, J. (2005) Prednisolone-induced changes in dystrophic skeletal muscle. FASEB J., 19, 834–836.
59. Ohlendieck, K. and Campbell, K.P. (1991) Dystrophin-associated proteins are greatly reduced in skeletal muscle from mdx mice. J. Cell Biol., 115, 1685–1694.
60. Ohlendieck, K., Matsumura, K., Ionasescu, V.V., Towbin, J.A., Bosch, E.P., Weinstein, S.L., Sernett, S.W. and Campbell, K.P. (1993) Duchenne muscular dystrophy: deficiency of dystrophin-associated proteins in the sarcolemma. Neurology, 43, 795–800.
61. Ibraghimov-Beskrovnaya, O., Ervasti, J.M., Leveille, C.J., Slaughter, C.A., Sernett, S.W. and Campbell, K.P. (1992) Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix. Nature, 355, 696–702.
62. Ervasti, J.M., Ohlendieck, K., Kahl, S.D., Gaver, M.G. and Campbell, K.P. (1990) Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature, 345, 315–319.
63. Greco, S., De Simone, M., Colussi, C., Zaccagnini, G., Fasanaro, P., Pescatori, M., Cardani, R., Perbellini, R., Isaia, E., Sale, P. et al. (2009) Common micro-RNA signature in skeletal muscle damage and regeneration induced by Duchenne muscular dystrophy and acute ischemia. FASEB J., 23, 3335–3346.
64. Raj, A. and van Oudenaarden, A. (2008) Nature, nurture, or chance: stochastic gene expression and its consequences. Cell, 135, 216–226.
65. Marotta, M., Ruiz-Roig, C., Sarria, Y., Peiro, J.L., Nuñez, F., Ceron, J., Munell, F. and Roig-Quilis, M. (2009) Muscle genome-wide expression profiling during disease evolution in mdx mice. Physiol. Genomics, 37, 119–132.
66. Frey, N., Richardson, J.A. and Olson, E.N. (2000) Calsarcins, a novel family of sarcomeric calcineurin-binding proteins. Proc. Natl Acad. Sci. U.S.A., 97, 14632–14637.
67. Chen, L., Li, J., Zhang, J., Dai, C., Liu, X., Wang, J., Gao, Z., Guo, H., Wang, R., Lu, S. et al. (2014) S100A4 promotes liver fibrosis via activation of hepatic stellate cells. J. Hepatol., doi:10.1016/j. jhep.2014.07.035.
68. Donato, R., Cannon, B.R., Sorci, G., Riuzzi, F., Hsu, K., Weber, D. J. and Geczy, C.L. (2013) Functions of S100 proteins. Curr. Mol. Med., 13, 24–57.
69. Abu El-Asrar, A.M., Nawaz, M.I., De Hertogh, G., Alam, K., Siddiquei, M.M., Van den Eynde, K., Mousa, A., Mohammad, G., Geboes, K. and Opdenakker, G. (2014) S100A4 is upregulated in proliferative diabetic retinopathy and correlates with markers of angiogenesis and fibrogenesis. Mol. Vis., 20, 1209–1224.
70. Schneider, M., Kostin, S., Strøm, C.C., Aplin, M., Lyngbaek, S., Theilade, J., Grigorian, M., Andersen, C.B., Lukanidin, E., Lerche Hansen, J. et al. (2007) S100A4 is upregulated in injured myocardium and promotes growth and survival of cardiac myocytes. Cardiovasc. Res., 75, 40–50.
71. Goetsch, S.C., Hawke, T.J., Gallardo, T.D., Richardson, J.A. and Garry, D.J. (2003) Transcriptional profiling and regulation of the extracellular matrix during muscle regeneration. Physiol. Genomics, 14, 261–271.
72. Gannoun-Zaki, L., Fournier-Bidoz, S., Le Cam, G., Chambon, C., Millasseau, P., Léger, J.J. and Dechesne, C.A. (1995) Down-regulation of mitochondrial mRNAs in the mdx mouse model for Duchenne muscular dystrophy. FEBS Lett., 375, 268–272.
73. Kuznetsov, A.V., Winkler, K., Wiedemann, F.R., von Bossanyi, P., Dietzmann, K. and Kunz, W.S. (1998) Impaired mitochondrial oxidative phosphorylation in skeletal muscle of the dystrophin-deficient mdx mouse. Mol. Cell. Biochem., 183, 87–96.
74. Tkatchenko, A.V., Piétu, G., Cros, N., Gannoun-Zaki, L., Auffray, C., Léger, J.J. and Dechesne, C.A. (2001) Identification of altered gene expression in skeletal muscles from Duchenne muscular dystrophy patients. Neuromuscul. Disord., 11, 269–277.
75. Iwama, E., Tsuchimoto, D., Iyama, T., Sakumi, K., Nakagawara, A., Takayama, K., Nakanishi, Y. and Nakabeppu, Y. (2011) Cancer-related PRUNE2 protein is associated with nucleotides and is highly expressed in mature nerve tissues. J. Mol. Neurosci., 44, 103–114.
76. Romaniello, R., Arrigoni, F., Bassi, M.T. and Borgatti, R. (2014) Mutations in α- and β-tubulin encoding genes: implications in brain malformations. Brain Dev., doi:10.1016/j.braindev. 2014.06.002.
77. Wilkinson, D.G. (2001) Multiple roles of EPH receptors and ephrins in neural development. Nat. Rev. Neurosci., 2, 155–164.
78. Luo, Z.G., Wang, Q., Zhou, J.Z., Wang, J., Luo, Z., Liu, M., He, X., Wynshaw-Boris, A., Xiong, W.C., Lu, B. et al. (2002) Regulation of AChR clustering by Dishevelled interacting with MuSK and PAK1. Neuron, 35, 489–505.
79. Kandarian, S.C. and Jackman, R.W. (2006) Intracellular signaling during skeletal muscle atrophy. Muscle Nerve, 33, 155–165.
80. Banks, G.B., Chamberlain, J.S. and Froehner, S.C. (2009) Truncated dystrophins can influence neuromuscular synapse structure. Mol. Cell. Neurosci., 40, 433–441.
81. Pratt, S.J.P., Shah, S.B., Ward, C.W., Kerr, J.P., Stains, J.P. and Lovering, R.M. (2014) Recovery of altered neuromuscular junction morphology and muscle function in mdx mice after injury. Cell. Mol. Life Sci., doi:10.1007/s00018-014-1663-7.
82. Saeed, A.I., Sharov, V., White, J., Li, J., Liang, W., Bhagabati, N., Braisted, J., Klapa, M., Currier, T., Thiagarajan, M. et al. (2003) TM4: a free, open-source system for microarray data management and analysis. BioTechniques, 34, 374–378.
83. Chen, J., Bardes, E.E., Aronow, B.J. and Jegga, A.G. (2009) ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res., 37, W305–W311.